-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
-
Summary
-
Halozyme Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2010 to 2023.
- Halozyme Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $12.6M, a 34.3% increase year-over-year.
- Halozyme Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $41.6M, a 21.7% increase year-over-year.
- Halozyme Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $36.6M, a 50.1% increase from 2022.
- Halozyme Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $24.4M, a 17.2% increase from 2021.
- Halozyme Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $20.8M, a 21% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)